Bedwetting, Nocturnal Enuresis, Urinary Incontinence
Conditions
Keywords
bedwetting, biometric, artificial intelligence, machine learning, heart rate variability, nocturnal enuresis, enuresis, urinary incontinence
Brief summary
Identify the dry night rate in patients using the GoGoband® nocturnal enuresis device vs a standard Pflaundler bedwetting alarm.
Detailed description
3.1 Problem Statement At the present time, there are no side-by-side comparison studies of GoGoband® vs SNEA. Since many of the prior studies were conducted using variable outcome parameters that makes direct comparisons of studies difficult it would be beneficial to obtain comparable data from the 2 groups and compare dry night rates for the 2 devices. 3.2 Purpose of Study/Potential Impact Our preliminary quality improvement data indicates that the GoGoband® is more efficacious than both medication and SNEA in an uncontrolled environment when deidentified data was analyzed off our servers. Our present database does not allow us to discern if patients are monosymptomatic nocturnal enuresis (MNE) or non monosymptomatic nocturnal enuresis (NMNE). Without this ability as well as for controlling for behavioral and academic problems which are known to affect outcomes in nocturnal enuresis studies, the investigators are not able to compare our results definitively and accurately to other treatment modalities. Hypothesis Our hypothesis is that the GoGoband® is more effective than SNEA and Desmopressin in the treatment of Nocturnal Enuresis Primary Objective The primary objective of this study is to determine whether the GoGoband®\] is as effective or more effective in comparison to children who use SNEA in a population of MNE patients with no underlying Attention deficit hyperactivity disorder (ADHD) in a 3 month period. Secondary Objectives To ascertain if familial incidence of nocturnal enuresis has an effect on outcomes 5.1 General Design Description The investigators propose the following study in patients who have been evaluated for primary nocturnal enuresis in our Yale New Haven Clinics. * All patients to be evaluated for nocturnal enuresis will undergo standard evaluation and initial treatment for nocturnal enuresis which includes: * Assessment Of Bowel Habits, * Fill Out A Questionnaire To Evaluate For Voiding Dysfunction * Treatment with routine bedwetting protocol of: 1. Stopping drinks 1 HR before bedtime, meals at least 3 hrs before bedtime, eliminating milk and ice cream from dinner and on, making sure that bowel movements are occurring 4 times per week and treating appropriately if necessary. 2. On return visit bedwetters and parents will be given the option of using medication , no further treatment, or alarm therapy. 3. If patients choose alarm therapy, they will be asked if they wish to participate in the Randomized study comparing GoGoband® vs SNEA. 4. Alarms will be provided to the patients free of cost to participants 5. Patients in the alarm group will be treated for 3 months continuously. 6. Patients in the SNEA group will record nightly if they wet their clothes and the report will be recorded and reviewed weekly 7. GoGoband® patients' data will be automatically saved on the HIPPA Compliant servers and subsequently reviewed at the end of the week.
Interventions
use of biometric alarm to wake patient prior to wetting
standard bedwetting alarm is used to treat patients, alarm sounds after wetting accident has occurred
Sponsors
Study design
Eligibility
Inclusion criteria
1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged 6 to 21 years 4. In good general health as evidenced by medical history and diagnosed with MNE 5. Ability to and be willing to adhere to the treatment regimen. -
Exclusion criteria
1. No patient may have had treatment of MNE in the past 6 months whether with medications or alarms 2. Current use of on ADHD medications, Tricyclics, SSRI's, NRI's or any antipsychotic medications. 3. Presence of Autistic Spectrum disorder, ADHD, genetic syndrome associated with developmental or learning disabilities 4. Treatment with another investigational drug or other intervention within last 6 months 5. Any form of Diabetes Mellitus or Diabetes Insipidus 6. No patient with known Chronic renal disease with moderate to severe renal impairment (defined as a creatinine clearance below 50mL/min). 7. No patient with known hyponatremia or a history of hyponatremia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Wet Nights | 3 month period | Comparison of alarms are to determine whether the GoGoband®\] is as effective or more effective in comparison to children who use SNEA in a population of MNE patients with no underlying ADHD. The number of wet nights in each group will be compared to each other providing a comparison of the data. The data will be compared using either a T test or Kruskal Wallis or anova depending on the number of comparisons performed and the data distribution is normal or not. If patient numbers are less than 10 per group no statistical analysis will be performed. |
Countries
United States
Contacts
Dept of Urology, Yale School of Medicine
Participant flow
Recruitment details
patients with NE were asked to participate in a study without compensation to evaluate different bedwetting alarms
Pre-assignment details
patients were assigned randomly to gogoband group and standard alarm therapy
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 9.8 years STANDARD_DEVIATION 2.6 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 13 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 12 Participants |
| Region of Enrollment United States | 16 participants |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 8 | 0 / 3 |
| other Total, other adverse events | 0 / 8 | 0 / 3 |
| serious Total, serious adverse events | 0 / 8 | 0 / 3 |